Skip to main content
S&P 5007,701.40-1.33%DOW51,477.88-0.37%NASDAQ26,622.97-2.14%BTC$81,589.00-1.90%ETH$2,423.72-3.41%GOLD$4,117.50-1.43%OIL$95.10+1.02%
Smart Investors Daily
SID Premium
BioMarin Pharmaceutical Inc. logo

NASDAQ · BMRN

BioMarin Pharmaceutical Inc.

Healthcare · Biotechnology

$54.38

Up+$0.48 (+0.88%)

Updated Oct 14, 2026, 7:08 PM

SID Score

5.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
10.18B
P/E ratio
19.56
Dividend yield
0.00%
52-week range
$49.26 – $70.98
Volume
2.66M
Avg. volume
2.67M

Price performance · BMRN

BMRN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 13, 2026

BMRN closed at $54.38 after 21 trading sessions, down 15.62% for the selected period.

Last close
$54.38
Period change
-15.62%
Period low
$54.38
Period high
$65.08
Daily close
View OHLC price history
BMRN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 13, 2026$55.30$55.655$53.93$54.382.66M
Oct 12, 2026$55.56$55.96$54.90$55.392.37M
Oct 9, 2026$54.80$55.975$54.48$54.7952.15M
Oct 8, 2026$54.95$54.97$53.899$54.893.1M
Oct 7, 2026$56.05$56.60$54.76$55.202.08M
Oct 6, 2026$57.54$57.875$55.76$56.223.72M
Oct 5, 2026$57.11$58.11$56.82$57.542.41M
Oct 2, 2026$58.52$58.73$57.15$57.182.19M
Oct 1, 2026$59.81$60.16$58.39$58.442.08M
Sep 30, 2026$59.90$60.705$59.37$60.001.8M
Sep 29, 2026$59.235$60.09$58.96$59.871.81M
Sep 28, 2026$59.87$60.07$58.74$59.462.36M
Sep 25, 2026$61.50$61.50$60.17$60.261.79M
Sep 24, 2026$62.21$62.33$61.125$61.351.66M
Sep 23, 2026$63.68$64.00$61.58$62.212.11M
Sep 22, 2026$64.34$64.79$63.35$63.371.96M
Sep 21, 2026$64.35$64.96$63.58$64.061.88M
Sep 18, 2026$65.25$65.29$63.84$63.944.46M
Sep 17, 2026$65.34$66.21$64.97$65.081.38M
Sep 16, 2026$64.48$65.67$64.34$64.732.25M
Sep 15, 2026$65.78$65.78$63.85$64.451.85M

Latest BMRN news

The latest Smart Investors Daily articles mentioning BMRN.

Stock researchCompany · Overview

BMRN research

Overview

Company profile and research snapshot.

Company profile

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$80.58
Implied upside
—
Analysts
—
BMRN recent ratings
DateFirmRatingTarget
Sep 10, 2026HC Wainwright & Co.Neutral—
Sep 1, 2026Piper SandlerOverweight—
Aug 31, 2026HC Wainwright & Co.Neutral—
Aug 31, 2026JefferiesBuy—
Aug 19, 2026BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia. The company will also share data from studies of the investigational long-acting medicine BMN 333.

Benzinga · Oct 9, 2026

BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction Growth

The data include encouraging new imaging results from a post-hoc analysis of a randomized, double-blind, placebo-controlled trial evaluating the effect of VOXZOGO on the growth of the foramen magnum and craniocervical

Yahoo · Oct 8, 2026

BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?

BioMarin Pharmaceutical (BMRN) just put fresh clinical data in front of investors, highlighting five year outcomes for POMBILITI plus OPFOLDA in late onset Pompe disease and early stage results for its nivudirsen program. BioMarin Pharmaceutical’s clinical updates arrive after a challenging spell for the stock, with the 30 day share price return down 17.03% and the 7 day move also weaker, while the 1 year total shareholder return remains close to flat at 0.93%. Scan BioMarin Pharmaceutical’s...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By